Skip to content
Levamlodipine
Conjupri (levamlodipine) is a small molecule pharmaceutical. Levamlodipine was first approved as Conjupri on 2019-12-19. It is used to treat hypertension in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Conjupri
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levamlodipine maleate
Tradename
Company
Number
Date
Products
CONJUPRICSPC Ouyi PharmaceuticalN-212895 RX2019-12-19
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
conjupriNew Drug Application2021-12-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypertensionEFO_0000537D006973I10
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C08: Calcium channel blockers
— C08C: Selective calcium channel blockers with mainly vascular effects
— C08CA: Dihydropyridine derivative selective calcium channel blockers with mainly vascular effects
— C08CA17: Levamlodipine
HCPCS
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
TrichuriasisD014257EFO_0007524B79———1—1
AscariasisD001196EFO_0007154B77———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179——4——4
Covid-19D000086382U07.1—12——2
Respiratory tract infectionsD012141J06.9——1——1
Acne vulgarisD000152EFO_0003894L70—11——1
Nephrotic syndromeD009404EFO_0004255N04——1——1
Colonic neoplasmsD003110C18——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Aplastic anemiaD000741HP_0001915D61.9—3——14
Hemolytic anemiaD000743D55-D59—3———3
ProteinuriaD011507HP_0000093R80—2———2
ThrombosisD013927—2———2
Paroxysmal hemoglobinuriaD006457Orphanet_447D59.12—2———2
Bone marrow failure disordersD000080983—2———2
HemoglobinuriaD006456R82.3—2———2
Urination disordersD014555—2———2
Hematologic diseasesD006402EFO_0005803D75.9—1———1
Immune system diseasesD007154D89.9—1———1
Show 5 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLEVAMLODIPINE
INNlevamlodipine
Description
Levamlodipine (INN), also known as levoamlodipine or S-amlodipine is a pharmacologically active enantiomer of amlodipine. Amlodipine belongs to the dihydropyridine group of calcium channel blocker used as an antihypertensive and antianginal agent. Levamlodipine is currently marketed in Russia under the brand name EsCordi Cor (Actavis Pharma), in Brazil under the brand name Novanlo (Biolab Sanus) and in India under the trade names Eslo (Zuventus Healthcare Ltd.), Asomex (Emcure Pharmaceutical Ltd.), and Espin (Intas Pharmaceuticals Ltd.).
Classification
Small molecule
Drug classphenylpyridine vasodilators; tricyclic compounds
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl
Identifiers
PDB—
CAS-ID103129-82-4
RxCUI—
ChEMBL IDCHEMBL2111097
ChEBI ID53796
PubChem CID9822750
DrugBankDB09237
UNII ID0P6NLP6806 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 111 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
347 adverse events reported
View more details